Safusidenib

DB18745InvestigationalSmall molecule

Safusidenib: Overview.

Mechanism: Pharmacologically active on Isocitrate dehydrogenase [NADP] cytoplasmic
Curator reviewed
Formula / weight: C₂₅H₁₈Cl₃FN₂O₄ · 535.78 g/mol (avg)
Also known as: (2E)-3-[1-[[5-(1-Fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl]carbonyl]-3-methyl-1H-indol-4-yl]-2-propenoic acid · 2-Propenoic acid, 3-[1-[[5-(1-fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl]carbonyl]-3-methyl-1H-indol-4-yl]-, (2E)- · AB-291 free acid · DS-1001 free acid

Resolves to

Compound

Structure

InChIKeyBOOMBLZEOHXPPX-BQYQJAHWSA-NSMILESCC1=CN(C(=O)C2=C(ON=C2C2=C(Cl)C=C(Cl)C=C2Cl)C(C)(C)F)C2=CC=CC(\C=C\C(O)=O)=C12

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Safusidenib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.